Prevalence of Stroke in Individuals with Sickle Cell Disease Pre- and during Hydroxyurea Uses: A Descriptive Cross-Sectional Study in Tanzania

Table 2

Prevalence of stroke pre- and post-HU use among participants (n = 228).

Variables	n (%)
Stroke status pre-hydroxyurea use
Yes	28 (12.3)
No	200 (87.7)
Stroke status post-hydroxyurea use
Yes	6 (2.6)
No	222 (97.4)
Range of hydroxyurea used per week in mg (minimum-maximum) 6000 (1000–7000)
Dosage of HU used per week (mg)
<3500	59 (25.9)
3500	132 (57.9)
>3500	37 (16.2)
Duration of HU use
< 2 years	132 (57.9)
≥ 2 years	96 (42.1)